X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
atezolizumab (658) 658
oncology (378) 378
nivolumab (364) 364
open-label (342) 342
pembrolizumab (335) 335
immunotherapy (315) 315
multicenter (283) 283
docetaxel (270) 270
chemotherapy (243) 243
humans (193) 193
cancer (158) 158
pd-l1 (142) 142
lung cancer (125) 125
metastasis (110) 110
tumors (95) 95
ipilimumab (93) 93
cancer therapies (88) 88
non-small cell lung cancer (86) 86
respiratory system (84) 84
patients (81) 81
pd-1 (81) 81
immune checkpoint (78) 78
immunology (78) 78
clinical trials (75) 75
female (75) 75
immune checkpoint inhibitors (73) 73
pd-l1 protein (70) 70
durvalumab (67) 67
male (67) 67
therapy (67) 67
nsclc (66) 66
care and treatment (65) 65
melanoma (65) 65
safety (64) 64
aged (63) 63
apoptosis (63) 63
middle aged (61) 61
biomarkers (59) 59
lung cancer, non-small cell (58) 58
non-small cell lung carcinoma (58) 58
single-arm (58) 58
expression (56) 56
blockade (55) 55
lung neoplasms - drug therapy (55) 55
survival (55) 55
cell lung-cancer (54) 54
immunotherapy - methods (54) 54
ligands (53) 53
prognosis (51) 51
antibodies, monoclonal - therapeutic use (50) 50
b7-h1 antigen - antagonists & inhibitors (50) 50
immunohistochemistry (50) 50
pharmacology & pharmacy (50) 50
lymphocytes (49) 49
review (49) 49
urothelial carcinoma (49) 49
avelumab (48) 48
mutation (48) 48
pd-l1 expression (48) 48
bladder cancer (47) 47
medical prognosis (47) 47
pd-1 blockade (47) 47
carcinoma, non-small-cell lung - drug therapy (46) 46
treatment outcome (46) 46
carcinoma (45) 45
adult (44) 44
antineoplastic agents - therapeutic use (43) 43
antineoplastic agents, immunological - therapeutic use (43) 43
medicine, research & experimental (43) 43
pd-1 protein (43) 43
analysis (42) 42
lung neoplasms - pathology (41) 41
metastases (41) 41
trial (40) 40
cell death (38) 38
checkpoint inhibitors (38) 38
programmed cell death 1 receptor - antagonists & inhibitors (38) 38
research (38) 38
studies (38) 38
cisplatin-ineligible patients (37) 37
immune checkpoint inhibitor (37) 37
randomized controlled-trial (36) 36
aged, 80 and over (35) 35
cisplatin (35) 35
urology & nephrology (35) 35
antibody (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
meta-analysis (34) 34
b7-h1 antigen - metabolism (33) 33
carboplatin (33) 33
immune system (32) 32
1st-line treatment (31) 31
medical research (31) 31
small cell lung carcinoma (31) 31
usage (31) 31
adverse events (30) 30
antibodies, monoclonal, humanized - therapeutic use (30) 30
bevacizumab (30) 30
non-small-cell lung cancer (30) 30
carcinoma, non-small-cell lung - pathology (29) 29
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (640) 640
German (9) 9
Russian (8) 8
French (4) 4
Chinese (2) 2
Korean (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 11/2018, Volume 78, Issue 22, pp. 6486 - 6496
Biomarkers such as programmed death receptor 1 ligand (PD-L1) expression, tumor mutational burden (TMB), and high microsatellite instability are potentially... 
CELL LUNG-CANCER | CTLA-4 BLOCKADE | REPAIR | PEMBROLIZUMAB | ONCOLOGY | IMMUNOTHERAPY | PD-1 BLOCKADE | OPEN-LABEL | ATEZOLIZUMAB | CLINICAL-RESPONSE | STAGE IV
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2019, Volume 9, Issue 1, p. 4278
To summarize the therapeutic effects of PD-1/PD-L1 inhibitors on patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting, we... 
SURVIVAL | MULTICENTER | MULTIDISCIPLINARY SCIENCES | OPEN-LABEL | ATEZOLIZUMAB | PHASE-3 | NIVOLUMAB | DOCETAXEL | TUMORS
Journal Article
Trends in immunology, ISSN 1471-4906, 6/2018, Volume 39, Issue 6, pp. 435 - 437
Tumors that elude infiltration by CD8 + T lymphocytes are particularly resistant to multiple forms of treatment, including immune checkpoint blockade. Stromal... 
microsatellite instability | tumor organoids | atezolizumab | tumor neo-antigens | PD-1 | mutational burden
Journal Article
The Oncologist, ISSN 1083-7159, 02/2020, Volume 25, Issue 2, pp. 94 - 98
There are currently seven approved immune checkpoint inhibitors (ICIs) for the treatment of various cancers. These drugs are associated with profound, durable... 
Hyperprogressive disease | Immune checkpoint inhibitors | Cancer clinical trials | Immunotherapy | RECIST | ONCOLOGY | PD-1 BLOCKADE | ATEZOLIZUMAB | MUTATIONS
Journal Article
Nature communications, ISSN 2041-1723, 2018, Volume 9, Issue 1, pp. 5361 - 10
Combining whole exome sequencing, transcriptome profiling, and T cell repertoire analysis, we investigate the spatial features of surgically-removed biopsies... 
CTLA-4 BLOCKADE | MULTICENTER | EVOLUTION | PD-1 BLOCKADE | ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | OPEN-LABEL | ATEZOLIZUMAB | NIVOLUMAB | DOCETAXEL | TUMORS | Toxicity | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Lymphocytes T | Gene expression | Loci | Heterogeneity | Immunology | Biopsy | Lymphocytes | Spatial heterogeneity | Tumors | Cancer
Journal Article
Cancer, ISSN 0008-543X, 2016, Volume 122, Issue 21, pp. 3344 - 3353
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1906 - 1918
Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK study of... 
NSCLC | Atezolizumab | Immune checkpoint therapy beyond disease progression | SURROGATE | MULTICENTER | FREE SURVIVAL | GUIDELINES | ANTIBODY | OPEN-LABEL | DOCETAXEL | MPDL3280A | ONCOLOGY | RESPIRATORY SYSTEM | NIVOLUMAB | CELL
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 2019, Volume 14, Issue 8, pp. 1440 - 1446
There is substantial variability in survival and response outcomes for patients using immune checkpoint inhibitors (ICIs), and predictive markers are required... 
Immune checkpoint inhibitor | marker | Prognostic | Predictive | Atezolizumab | MULTICENTER | OPEN-LABEL | DOCETAXEL | CHEMOTHERAPY | CHECKPOINT INHIBITORS | ONCOLOGY | RESPIRATORY SYSTEM | 1ST-LINE
Journal Article
TRANSLATIONAL LUNG CANCER RESEARCH, ISSN 2218-6751, 08/2019, Volume 8, Issue 4, pp. 553 - 555
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2018, Volume 115, Issue 43, pp. E10119 - E10126
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 05/2018, Volume 10, Issue Suppl 13, pp. S1556 - S1563
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 44, pp. 27460 - 27470
Cancer immunotherapy has been revolutionised by drugs that enhance the ability of the immune system to detect and fight tumors. Immune checkpoint therapies... 
Head and neck cancer | Biomarkers for PD1-PD-L1 checkpoint therapy | Tumor-educated platelets | Atezolizumab
Journal Article